- Sun Pharmaceutical Industries received US FDA approval for its new drug application for XiminoTM extended-release capsules to treat acne. The capsules are indicated for inflammatory lesions of moderate to severe acne vulgaris in patients aged 12 and older. - DLF Ltd sold four acres of land in Kochi for Rs. 111 crore as part of its plan to sell non-core assets to boost cash flows and reduce debt. - US and European stock markets plunged last week amid fears about China's economic slowdown and global growth, with the Dow Jones Industrial Average entering correction territory.

1. SEBI Certified – Research Analyst www.choiceindia.com
Global View
India Update
Today’s Event/ Stock in News
Drug major Sun Pharmaceutical Industries said that it has received approval from the US health regulator for its new drug application for acne treatment
medicine--XiminoTM extended-release capsules. The US Food and Drug Administration (USFDA) has approved the company's supplemental New Drug
Application (sNDA) for XiminoTM (Minocycline HCl) extended-release capsules in strengths of 45 mg, 90 mg and 135 mg, Sun Pharma said in a statement.
XiminoTMextended-releasecapsulesareindicatedforinflammatorylesionsofnon-nodularmoderatetosevereacnevulgarisinpatients12yearsofageand
older. "This approval further strengthens the company's branded dermatology portfolio in the US. It expects XiminoTM extended-release capsules to be
available for patients during the fourth quarter of 2015," the Mumbai-based company said. Sun Pharma is the world's fifth largest specialty generic
pharmaceutical company and India's top pharmaceutical firm. The company's consolidated revenues for 12 months ended March 2015 stood at around
USD4.5billion,ofwhichUScontributedUSD2.2billion.
Technical Outlook : On daily chart, the stock has broke out rally of 61.8% of Fibonacci level previous top also stock is trading above 50 and 200 DMA
which indicates price could continue trade on higher note. Bullish crossover in RSI indicates bullishness to continue even volume increasing on daily
basis.Sofortradingprospective,onecaninitiatelong intherangeof 935/940 forthetargetof960/980 levels.
Realty major DLF Ltd has sold four acres of land in Kochi for Rs 111 crore as part of its plan to sell non-core assets to boost cash flows and reduce debt.
"We have sold a land parcel in Kochi for Rs 111 crore," DLF Group Chief Financial Officer (CFO) Ashok Tyagi told agency. The land was sold earlier this
monthtoalocaldeveloper.DLFhasbeensellingnon-corelandparcelandbusinessesforthelastthree-fouryearstofocusonitscorerealestatebusiness
as well as to improve its cash flows and reduce debt. DLF recently sold its cinema business DT Cinema for Rs 500 crore. It had sold last year hospitality
chain Amanresorts to its original founder Adrian Zecha for about Rs 2,200 cr. That apart, the company has exited from insurance and wind energy
businesses.In2012,DLFhadsold17acrelandparceltoLodhagroupforRs2,700cr.Inviewofsluggishhousingsalesandhighdebt,DLFislookingtoraise
privateequityfundsatprojectslevelandalsopartiallymonetiseitsrentalproperties,whichcomprisesofabout30million sqftwithRs2,400croreannual
rentalincome.DLF'snetdebt increased toRs21,598crasonJune30,from Rs20,965cr attheendoftheMarchquarter.Ofthetotaldebt,thecompany
said that thenetdebt attributabletodevelopmentbusiness(DevCo)wasRs7,598cr while Rs14,000crpertained torentalarm (RentCo).Last week, DLF
reported5%declineinnetprofittoRs121.55croreforthequarterendedJune30,duetohigherfinancecostandriseinoperationalexpenses.
TechnicalOutlook:Onderivativefront,inRealtysector,DLFwasascriptwhereShortBuiltUphasbeenperceivedwith5%negativepricechangeand
9% negative open interest change, shows Investors are bearish on the counter and creating short side position. Looking more closely on daily chart,
Sellingpressureathigherlevelsisbeingwitnessedinpreviousfewtradingsessionsthereforebearishsignalsontheweekarebeingconfirmed.RSI &
MACDinsellmodesupportsthebearishview.Sofortradingprospective,onecanshortintherangeof113/115forthetargetof108/102levels.
Sun Pharma.
DLF
SEBI Registered – Research Analyst www.choicebroking.in * Please Refer Disclaimer on Website
Morning Tea
24th Aug 2015
U.S.stocksplungedFriday,cappingaweekofcarnagethatsenttheDowJonesIndustrialAverageintocorrectionterritoryasfearsaboutChina’seconomy
andglobalgrowthspurredheavyselling.TheDowJonesIndustrialAverageDJIA,-3.12% plummeted530.94points,or3.1%,tocloseat16,459.75,TheS&P
500 SPX, -3.19% fell 64.84 points, or 3.2%, to settle at 1,970.89. On the other hand European stocks fell into correction territory Friday, as the market's
worst weekofthe year roundedoffwith downbeat datafrom ChinaandGreece facing asnapelection.TheStoxx Europe 600fell1.3%to368.59, with all
sectorsinthered.Theindexisdown11%fromitsall-timehighof414.06,hitonApril15.
China's stock markets joined the widespread selloff on Monday amid fears surrounding the economic slowdown in the world's second-
biggest economy. China's benchmark Shanghai Composite index opened down as much as 5.2 percent to 3,321.4, even as authorities
allowed pension funds managed by local governments to invest in the stock market for the first time over the weekend. Nifty likely to
open gap down .
Sell in the range of 113/115 with of SL 118.50 for the Target of 108/102.
Buy in the range of 935/940 with of SL 921 for the Target of 960/980.

2. SEBI Certified – Research Analyst www.choiceindia.com
Bulk Deal
Corporate Action / Result Calendar
SEBI Certified – Research Analyst www.choiceindia.com
Morning Tea
24th Aug 2015
Security in Ban
SEBI Registered – Research Analyst www.choicebroking.in * Please Refer Disclaimer on Website
IBREALEST, JINDALSTEL & INDIACEMENT
Corporate Action: Hinduja Global Solutions Limited: Interim Dividend - Rs 5/- Per Share.
Kaveri Seed Company Limited: Interim Dividend - Rs 2.50/- Per Share
Garware Wall Ropes Limited: Dividend - Rs 3/- Per Share.
Sr.No DealDate SecurityCode SecurityName ClientName DealType Quantity Price
1 21/08/2015 504879 ORIENTABRA PACESTOCKBROKINGSERVICESPVTLTD B 2,500,000 4.15
2 21/08/2015 504879 ORIENTABRA AJAYRAJGARHIA S 2,500,000 0.44
3 21/08/2015 533704 ESSARSHPNG INDIACAPITAL MARKETSPVTLTD B 1,450,000 0.43
4 21/08/2015 533704 ESSARSHPNG MANPHOOL EXPORTSLIMITED S 1,450,000 8.04
5 21/08/2015 532351 AKSHOPTFBR ARUNSOOD S 850,000 3.63
6 21/08/2015 538295 KAUSAMBI HETAKALPESHKUMAR GOLWALA S 662,493 8
7 21/08/2015 538295 KAUSAMBI HETAKALPESHKUMAR GOLWALA B 652,355 8.02
8 21/08/2015 539251 NIRVIKARA NARENDRAANOPCHANDMEHTA B 333,256 3.6
9 21/08/2015 538295 KAUSAMBI DIWAKAR SHESHANSHETTY S 293,664 70
10 21/08/2015 524084 MONSANTO MONSANTO INVESTMENTSINDIAPVTLTD B 285,000 70

3. SEBI Certified – Research Analyst www.choiceindia.com
Contact Us
www.choiceindia.com
www.choiceindia.comcustomercare@choiceindia.com
Disclaimer
This is solely for information of clients of Choice Broking and does not construe to be an investment advice. It is also not intended as an offer or solicitation for the purchase and sale of any financial
instruments. Any action taken by you on the basis of the information contained herein is your responsibility alone and Choice Broking its subsidiaries or its employees or associates will not be liable in
any manner for the consequences of such action taken by you. We have exercised due diligence in checking the correctness and authenticity of the information contained in this recommendation, but
Choice Broking or any of its subsidiaries or associates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the
information contained in this recommendation or any action taken on basis of this information. Technical analysis studies market psychology, price patterns and volume levels. It is used to forecast
future price and market movements. Technical analysis is complementary to fundamental analysis and news sources. The recommendations issued herewith might be contrary to recommendations
issued by Choice Broking in the company research undertaken as the recommendations stated in this report is derived purely from technical analysis. Choice Broking has based this document on
information obtained from sources it believes to be reliable but which it has not independently verified; Choice Broking makes no guarantee, representation or warranty and accepts no responsibility
or liability as to its accuracy or completeness. The opinions contained within the report are based upon publicly available information at the time of publication and are subject to change without
notice. The information and any disclosures provided herein are in summary form and have been prepared for informational purposes. The recommendations and suggested price levels are intended
purely for trading purposes. The recommendations are valid for the day of the report however trading trends and volumes might vary substantially on an intraday basis and the recommendations may
be subject to change. The information and any disclosures provided herein may be considered confidential. Any use, distribution, modification, copying, forwarding or disclosure by any person is
strictly prohibited. The information and any disclosures provided herein do not constitute a solicitation or offer to purchase or sell any security or other financial product or instrument. The current
performance may be unaudited. Past performance does not guarantee future returns. There can be no assurance that investments will achieve any targeted rates of return, and there is no guarantee
against the loss of your entire investment.
POTENTIAL CONFLICT OF INTEREST DISCLOSURE (as on date of report) Disclosure of interest statement – • Analyst interest of the stock /Instrument(s): - No. • Firm interest of the stock /
Instrument (s): - No.
SEBI Certified – Research Analyst www.choiceindia.com
Research Team
Mr. Sumeet Bagadia Associate Director
Chandrakant Maske Research Associate
Kunal Parmar Research Associate
Ritesh Patel Research Associate
Amit Pathania Research Associate
Vikas Chaudhari Research Associate
Rajnath Yadav Research Associate
Satish Kumar Research Associate
Morning Tea
24th Aug 2015
SEBI Registered – Research Analyst www.choicebroking.in * Please Refer Disclaimer on Website